Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Doyle

Showing results (311-320 of 600) with videos related to

Pageof 60
Sort By:
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Nature Communications|July 2, 2026
L-type pyocins inhibit the BAM complex to kill without cell entryFabian Munder, Matthew D Johnson, Imogen Samuels, et al.
Circulation|August 30, 2021
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized TrialRenato D Lopes, Celestia S Higano, Susan F Slovin, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
ATS Scholar|April 19, 2021
Balancing Demands: Determinants of Burnout Reported by Fellows in Pulmonary and Critical Care MedicineJacqueline O'Toole, Sandra Zaeh, Michelle N Eakin, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 60

Showing results (311-320 of 600) with videos related to

Sort By:
Pageof 60
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Nature Communications|July 2, 2026
L-type pyocins inhibit the BAM complex to kill without cell entryFabian Munder, Matthew D Johnson, Imogen Samuels, et al.
Circulation|August 30, 2021
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized TrialRenato D Lopes, Celestia S Higano, Susan F Slovin, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
ATS Scholar|April 19, 2021
Balancing Demands: Determinants of Burnout Reported by Fellows in Pulmonary and Critical Care MedicineJacqueline O'Toole, Sandra Zaeh, Michelle N Eakin, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 60